Cevostamab

Cevostamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Cevostamab 研究

• To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  I 期招募中法国西班牙NCT07629583

• Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  III 期招募中美国澳大利亚Brazil加拿大NCT07555938

• Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  II 期招募中德国NCT07825064

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  I 期招募中美国澳大利亚加拿大CzechiaNCT04910568

• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  I 期招募中美国法国GreeceIsraelNCT05137054

• A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

  I 期 / II 期招募中澳大利亚法国德国PolandNCT05583617

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

  I 期招募中澳大利亚IsraelSouth KoreaNCT05927571

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。